Cargando…
Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium
BACKGROUND: Guidelines recommend omalizumab in patients with uncontrolled severe allergic asthma. We investigated real-life use of omalizumab, the proportion of patients fulfilling eligibility criteria, its costs and its effectiveness. METHOD: In a cohort of asthma patients initiating treatment with...
Autores principales: | Verhamme, Katia M.C., Lucet, Catherine, Van Meerhaeghe, Alain, Brusselle, Guy G.O., Lambert, Marie-Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876130/ https://www.ncbi.nlm.nih.gov/pubmed/31777749 http://dx.doi.org/10.1183/23120541.00253-2018 |
Ejemplares similares
-
Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
por: De Castro, Giovanna, et al.
Publicado: (2013) -
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017) -
A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in Belgium
por: Lapeere, H., et al.
Publicado: (2019) -
Efficacy and safety of the use of omalizumab in a patient with difficult-to-control severe asthma and antiphospholipid antibody syndrome
por: Villela, Rosangela, et al.
Publicado: (2015) -
Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2013)